A novel family of small molecule HIF-1 alpha stabilizers for the treatment of diabetic wounds; an integrated in silico, in vitro, and in vivo strategy

被引:8
|
作者
Esakkimuthukumar, M. [1 ]
Swaroop, Akey Krishna [1 ]
Patnaik, Sunil Kumar [1 ]
Kumar, Rajesh R. [2 ]
Praveen, T. K. [3 ]
Naik, Mudavath Ravi [3 ]
Jubie, S. [1 ]
机构
[1] JSS Acad Higher Educ & Res, JSS Coll Pharm, Dept Pharmaceut Chem, Ooty, Tamil Nadu, India
[2] JSS Acad Higher Educ & Res, JSS Coll Pharm, Dept Pharmaceut Biotechnol, Ooty, Tamil Nadu, India
[3] JSS Acad Higher Educ & Res, JSS Coll Pharm, Dept Pharmacol, Ooty, Tamil Nadu, India
关键词
MODEL;
D O I
10.1039/d2ra05364k
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Hypoxia-inducible factor-1 alpha (HIF-1 alpha) is a crucial regulator of wound healing, which includes epithelialization, angiogenesis, granulation, tissue development, and wound contraction. Even though diabetic wounds are hypoxic, HIF-1 alpha levels are decreased during healing. Diabetic wound healing necessitates the modulation of hypoxia-induced responses by VHL-HIF-1 alpha protein-protein inhibition. Our proposed hypothesis is to increase HIF-1 alpha levels by inhibiting VHL and HIF-1 alpha interactions by novel small bioactive molecules, accelerating diabetic wound healing. A three features (two aromatic rings and one hydrogen bond acceptor) pharmacophore hypothesis was generated from the existing HIF-1 alpha modulators. Virtual screening was done based on the generated pharmacophore, and a library consisting of the top 20 out of 3728 compounds was selected using ZINCPharmer. Of the top 20 molecules, the pyrazole moiety was identified as the top "HIT". Five analogues of pyrazole were designed, and Scifinder ascertained the novelty. The designed compounds were synthesized and characterized by IR, Mass, and NMR. Preliminarily, we have carried out a scratch wound assay using 3T3L1 cell lines. All the synthesized compounds showed significant wound healing activity. Further, to validate the in vitro assay, the compound CI, which showed effective in vitro results was used for in vivo study. Using the diabetes mouse model, comprising streptozotocin-induced (STZ) diabetic mice and scratch wound assay, we demonstrated that inhibiting the VHL and HIF-1 alpha connection is a promising strategy for treating diabetic ulcers. Molecules CI and CP were found to have substantial in silico, in vitro, and in vivo outcomes.
引用
收藏
页码:31293 / 31302
页数:10
相关论文
共 35 条
  • [21] In vitro and in vivo antitumor activities of T-3764518, a novel and orally available small molecule stearoyl-CoA desaturase 1 inhibitor
    Nishizawa, Satoru
    Sumi, Hiroyuki
    Satoh, Yoshihiko
    Yamamoto, Yukiko
    Kitazawa, Satoshi
    Honda, Kohei
    Araki, Hideo
    Kakoi, Kazuyo
    Imamura, Keisuke
    Sasaki, Masako
    Miyahisa, Ikuo
    Satomi, Yoshinori
    Nishigaki, Ryuuichi
    Hirayama, Megumi
    Aoyama, Kazunobu
    Maezaki, Hironobu
    Hara, Takahito
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2017, 807 : 21 - 31
  • [22] Differential role of carcinoembryonic antigenrelated cell adhesion molecule (CEACAM-1) during interferon-alpha treatment of HCV infection in vivo and in vitro
    Hilgard, P
    Broering, R
    Trippler, M
    Siepen, MAD
    Viazov, S
    Gerken, G
    Schlaak, J
    HEPATOLOGY, 2005, 42 (04) : 560A - 560A
  • [23] In Vitro Evaluation of a Novel mRNA-Based Therapeutic Strategy for the Treatment of Patients Suffering from Alpha-1-Antitrypsin Deficiency
    Michel, Tatjana
    Kankura, Anna
    Medina, Martha L. Salinas
    Kurz, Julia
    Behring, Andreas
    Avci-Adali, Meltem
    Nolte, Andrea
    Schlensak, Christian
    Wendel, Hans Peter
    Krajewski, Stefanie
    NUCLEIC ACID THERAPEUTICS, 2015, 25 (05) : 235 - 244
  • [24] An Orally Administered Small Molecule That Inhibits Hepatic Sulfatase-2 Expression In Vivo: A Novel Strategy to Correct Diabetic Dyslipoproteinemia With Implications for Residual Atherosclerotic Cardiovascular Disease (ASCVD) Risk
    Bisgaier, Charles L.
    Oniciu, Daniela C.
    Williams, Kevin Jon
    CIRCULATION, 2017, 136
  • [25] A novel strategy for the treatment of chronic wounds based on the topical administration of rhEGF-loaded lipid nanoparticles: In vitro bioactivity and in vivo effectiveness in healing-impaired db/db mice
    Gainza, Garazi
    Pastor, Marta
    Javier Aguirre, Jose
    Villullas, Silvia
    Luis Pedraz, Jose
    Maria Hernandez, Rosa
    Igartua, Manoli
    JOURNAL OF CONTROLLED RELEASE, 2014, 185 : 51 - 61
  • [26] A novel small-molecule antagonist enhances the sensitivity of osteosarcoma to cabozantinib in vitro and in vivo by targeting DNMT-1 correlated with disease severity in human patients
    Wang, Ji-Hai
    Zeng, Zhen
    Sun, Jie
    Chen, Yan
    Gao, Xudong
    PHARMACOLOGICAL RESEARCH, 2021, 173
  • [27] Inhibition of tyrosine phosphorylation of the novel MEK1 substrate MACC1 by clinically approved small molecule drugs inhibits proliferation and motility in vitro and metastasis formation in vivo
    Kobelt, Dennis
    Perez-Hernandez, Daniel
    Fleuter, Claudia
    Dahlmann, Mathias
    Smith, Janice
    Zincke, Fabian
    Migotti, Rebekka
    Walther, Wolfgang
    Schlag, Peter M.
    Dittmar, Gunnar
    Stein, Ulrike
    CLINICAL & EXPERIMENTAL METASTASIS, 2017, 34 (08) : 507 - 507
  • [28] Integrated Transcriptomic and Proteomic Study of the Mechanism of Action of the Novel Small-Molecule Positive Allosteric Modulator 1 in Targeting PAC1-R for the Treatment of D-Gal-Induced Aging Mice
    Liang, Lili
    Chen, Shang
    Su, Wanlin
    Zhang, Huahua
    Yu, Rongjie
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (07)
  • [29] PF-06463922, a novel brain-penetrating small molecule inhibitor of ALK/ROS1 with potent activity against a broad spectrum of ALK resistant mutations in preclinical models in vitro and in vivo
    Zou, Helen Y.
    Engstrom, Lars R.
    Li, Qiuhua
    Lu, Melissa West
    Tang, Ruth Wei
    Wang, Hui
    Tsaparikos, Konstantinos
    Wang, Jinwei
    Timofeevski, Sergei
    Dinh, Dac M.
    Lam, Hieu
    Lam, Justine
    Yamazaki, Shinji
    Hu, Wenyue
    Affolter, Timothy
    Lappin, Patrick B.
    Gukasyan, Hovhannes
    Lee, Nathan
    Tursi, Jennifer M.
    Johnson, Ted W.
    Fantin, Valeria
    Smeal, Tod
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [30] A new disulfide-linked dimer of a single-chain antibody fragment against human CD47 induces apoptosis in lymphoid malignant cells in vitro and in vivo via the HIF-1α pathway:: A possible novel therapeutic agent for B-CLL.
    Sagawa, Morihiko
    Shimizu, Takatsune
    Xian, Mingji
    Chizuka, Aki
    Fukushima, Naoshi
    Kinoshita, Yasuko
    Ohizumi, Iwao
    Ikeda, Yasuo
    Okabe, Hisafumi
    Kizaki, Masahiro
    BLOOD, 2006, 108 (11) : 594A - 594A